Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Sadler

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
ACS Medicinal Chemistry Letters|October 18, 2019
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial ActivityManjunatha M R, Radha Shandil, Manoranjan Panda, et al.
ACS Chemical Biology|July 19, 2014
Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coliShahul Hameed P, Praveena Manjrekar, Murugan Chinnapattu, et al.
Pharmacology & Therapeutics|January 31, 2017
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injuryDaniel F Carr, Seyoum Ayehunie, Andrea Davies, et al.
Bioorganic & Medicinal Chemistry|December 9, 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidaseSudhir Landge, Amrita B Mullick, Kavitha Nagalapur, et al.
Journal of Medicinal Chemistry|May 31, 2014
Lead optimization of 1,4-azaindoles as antimycobacterial agentsPravin S Shirude, Radha K Shandil, M R Manjunatha, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|November 13, 2013
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivoPravin S Shirude, Radha Shandil, Claire Sadler, et al.
Nature Communications|September 18, 2024
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infectionsShahul Hameed P, Harish Kotakonda, Sreevalli Sharma, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
ACS Medicinal Chemistry Letters|October 18, 2019
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial ActivityManjunatha M R, Radha Shandil, Manoranjan Panda, et al.
ACS Chemical Biology|July 19, 2014
Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coliShahul Hameed P, Praveena Manjrekar, Murugan Chinnapattu, et al.
Pharmacology & Therapeutics|January 31, 2017
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injuryDaniel F Carr, Seyoum Ayehunie, Andrea Davies, et al.
Bioorganic & Medicinal Chemistry|December 9, 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidaseSudhir Landge, Amrita B Mullick, Kavitha Nagalapur, et al.
Journal of Medicinal Chemistry|May 31, 2014
Lead optimization of 1,4-azaindoles as antimycobacterial agentsPravin S Shirude, Radha K Shandil, M R Manjunatha, et al.
Cancer Research|March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical ModelsHazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry|November 13, 2013
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivoPravin S Shirude, Radha Shandil, Claire Sadler, et al.
Nature Communications|September 18, 2024
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infectionsShahul Hameed P, Harish Kotakonda, Sreevalli Sharma, et al.
Nature Communications|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trialJean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Pageof 2